Medtronic wins FDA expanded approval for Valiant thoracic stent graft system

The FDA awards medical device maker Medtronic expanded premarket approval for its Valiant thoracic stent grafting system to treat lesions in the descending thoracic aorta.

Medical device giant Medtronic [1] (NYSE:MDT [2]) won expanded FDA approval to treat additional types of descending thoracic aorta lesions with its Valiant thoracic stent graft system.

The Valiant graft with the Captivia delivery system is now indicated to treat all DTA lesions, with the exception of dissections, and is only the 2nd endovascular stent grafting device approved to treat isolated lesions of the thoracic aorta, the FDA noted.